ロード中...
The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions
BACKGROUND: Rivastigmine is the only cholinesterase inhibitor (ChEI) available as transdermal patch. The patch was developed to improve gastrointestinal tolerability and treatment adherence to higher dosages as compared with oral medication. Preferences of patients and caregivers for the patch were...
保存先:
| 出版年: | Int J Clin Pract |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BlackWell Publishing Ltd
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4237461/ https://ncbi.nlm.nih.gov/pubmed/24588972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12374 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|